A phase 2 study in children will also start early in ... gradually adding new versions of Prevnar that expand the number of serotypes covered, but analysts think that position is now under threat.

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Nintendo Switch 2 is finally confirmed. After literal years of unverified rumors, dubious leaks and copious amounts of online speculation, Nintendo has lifted the lid on its next-generation ...

In fact, in study 2, in which a strong study center effect was identified, all PCV7 serotypes, including serotypes 6B and 23F, met noninferiority criteria when the analyses were repeated with an ...

Neomycin is an antibiotic that interferes with bacterial protein synthesis by binding primarily to the 30S subunit of bacterial ribosomes. Many vaccines contain trace amounts of neomycin to ...